SOLTI-2101 HARMONIA
Clinical Trial Program
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer
Phase III
Status
Recruiting
Tumour subtype:
HR+, Biomarker driven
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Aleix Prat, MD, PhD (Hospital Clínic, Barcelona, Spain)
Lisa A. Carey, MD (Lineberger Comprehensive Cancer Center. Chapel Hill, NC, US)
Dan G. Stover, MD (Stefanie Spielman Comprehensive Breast Center. Columbus, OH, US)
Tomás Pascual, MD (SOLTI Scientific Director, Barcelona, Spain)
